A study from the University of Cincinnati has uncovered differences in pancreatic tumors that could explain why the cancer affects patients differently, potentially leading to more tailored treatments. The research, published in the journal Cancer Research, examined 22 pancreatic tumors from patients of varying racial backgrounds across the United States, including seven Black patients and 15 non-African American patients.

Researchers observed that tumors from Black patients exhibited fewer of the most common type of pancreatic cancer cells. Instead, these tumors contained more cells with a mix of diverse characteristics. While some of these varied cell types have been linked to drug resistance, the study did not establish a direct correlation with patient treatment outcomes.

Furthermore, the study found a higher presence of B cells, a type of immune cell, and larger clusters of these cells within the tumors of Black patients. Some B cells showed signs of potentially suppressing the body's anti-cancer immune response, though the full significance of these findings remains unclear.

Dr. Raymond Wadlow, a gastrointestinal medical oncologist at Inova Schar Cancer Institute, who was not involved in the study, noted that pancreatic cancer has presented significant challenges for immunotherapy, where the immune system is harnessed to fight the disease. He explained that pancreatic tumors can subvert the immune system, causing it to work against the body rather than for it.

Lead study author Nina Steele, Ph.D., an assistant professor at UC’s College of Medicine, emphasized the importance of including diverse patient populations in cancer research. "This study shows that ignoring diverse ancestry in medical research leaves blind spots in the search for a cure," Steele stated.

Wadlow commented that while tumors may share major DNA mutations, their cellular behavior and interaction with the immune system and surrounding tissue can vary considerably. He suggested these variations might differ across patient populations, potentially impacting both understanding disparities in pancreatic cancer and developing individualized treatments.

Steele acknowledged limitations in the current findings, noting that the study has not yet determined how the intermediate tumor cells influence survival or respond to standard chemotherapy. Future research will also investigate pancreatic tissue from individuals without cancer to better understand when these cellular differences emerge.

Wadlow cautioned that race and genetic ancestry alone do not account for all environmental, socioeconomic, and biological factors that could contribute to these findings. He stressed the need for larger studies with diverse patient groups to confirm whether these observed differences affect treatment outcomes or survival, adding that "While intriguing, these findings are still a long way from changing patient care."

Wadlow also recommended that newly diagnosed patients inquire about hereditary genetic testing, which can identify inherited mutations that may affect family members. Steele concluded that the findings highlight the necessity for clinical trials to accurately represent the diverse population affected by pancreatic cancer, ensuring that treatments benefit all patients, not just a subset.